secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2023-03-09T23:59:59+00:00
Accession:  0001193125-23-065459
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio Pharma prices $150M public offering of common stock at $17.00/share
-----------------------------------------------------------------------------

- Offering of 8,823,530 shares (plus underwriters' 30-day option for 1,323,529 shares) at $17.00/share.
- Gross proceeds ~$150M; net proceeds ~$143.1M after underwriting discounts and expenses.
- Expected use of proceeds: fund clinical/pre-clinical development, research, working capital, and potential acquisitions.
- Expected closing on or around March 10, 2023.
- Goldman Sachs, Evercore, Morgan Stanley, and KKR Capital Markets are book-running managers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000119312523065459/0001193125-23-065459-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000119312523065459/d463641d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-065459

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer